Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

David Malka, Pascale Cervera, Stéphanie Foulon, +21

The Lancet Oncology

Advanced Biliary-tract CancerGastrointestinal OncologyMedicineBiliary CancerNon-comparative Phase 2 +5

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

U. Vanhoefer, Mitra Tewes, Federico Rojo, +10

Journal of Clinical Oncology

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein, +14

Annals of Oncology

Surgical OncologyHepatologyGastrointestinal OncologyMedicineGastroenterology +8

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch‐Becker, Ullrich Graeven, Christian Lerchenmüller, +14

The Lancet Oncology

Maintenance StrategiesAio 0207MedicineCancer ManagementColorectal Cancer +5

Operations for Intrahepatic Cholangiocarcinoma: Single-Institution Experience of 158 Patients

Hauke Lang, Georgios C. Sotiropoulos, George Sgourakis, +8

Journal of the American College of Surgeons

A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)

J. Randolph Hecht, Tanja Trarbach, E. Jaeger, +7

Journal of Clinical Oncology

Tyrosine KinasePathologySurgeryOncologyGastrointestinal Oncology +15

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Tanja Trarbach, Markus Moehler, Volker Heinemann, +6

British Journal of Cancer

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

J. Randolph Hecht, Tanja Trarbach, John D. Hainsworth, +13

Journal of Clinical Oncology

Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

Michael I. Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, +9

Clinical Cancer Research

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion

Karin Potthoff, Ralf‐Dieter Hofheinz, Jessica C. Hassel, +9

Annals of Oncology

MedicineCutaneous BiologyInterdisciplinary ManagementClinical DermatologyTranslational Research +3